A B S T R A C T In an attempt to delineate the mechanism and the site of action of cyproheptadine and dopaminergic agonists as well as hormones including thyrotropin-releasing hormone (TRH) and hydrocortisone, the effects of these substances on ACTH secretion from corticotroph adenoma cells in culture were examined. Dispersed cells of pituitary adenomas obtained at surgery from four patients with Nelson's syndrome and one subject with Cushing's disease formed a monolayer and actively secreted ACTH into the medium. When TRH (0.1,UM) was added to the medium, a significant increase in ACTH secretion was demonstrated by adenoma cells from two patients who responded to TRH preoperatively. Moreover, a doseresponse relationship between TRH concentrations and ACTH secretion was observed. Incubation of cells with cyproheptadine (1 or 0.1 ,uM) resulted in a significant decrease in ACTH release, and inhibited stimulation produced by TRH in one experiment. This effect of cyproheptadine was blocked when equimolar concentrations of serotonin was coincubated, whereas serotonin by itself did not affect ACTH secretion. Dopamine (0.1 ,uM) lowered ACTH accumulation in the medium, which was blocked by the addition of haloperidol. When hydrocortisone was added to the culture, dose-dependent suppression of ACTH secretion was demonstrated. TRH at an equimolar concentration reversed this effect, but, failed to overcome the inhibition induced by a higher concentration of hydrocortisone in cells from one adenoma studied. Cultured normal corticotrophs obtained from a patient
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INTRODUCTION
Long-term administration of cyproheptadine, a serotonin antagonist, was found by Krieger et al. (1) to suppress the circulating levels of ACTH and to offer concomitant beneficial clinical effects in patients with Cushing's disease. Subsequent studies confirmed the efficacy of this drug in the management of some, though not all, patients with Cushing's disease and Nelson's syndrome (2) (3) (4) (5) (6) (7) (8) . Bromocriptine, a dopaminergic agonist, likewise has been shown to lower plasma ACTH levels in some patients, and its clinical use is currently being evaluated (9) (10) (11) (12) (13) (14) (15) . These works opened the possibility of medical management of the disorder. The mechanism by which these drugs inhibit ACTH secretion, however, remains unknown.
It has been recently shown, on the other hand, that pituitary microadenomas are found in the majority of patients with Cushing's disease and that selective removal of the tumor corrects hypercortisolism in these patients (16) (17) (18) (19) . Although drugs such as cyproheptadine and bromocriptine that modulate the activity of neurotransmitters may act on the central nervous system, a direct action on a pituitary adenoma has not been ruled out. We have recently demonstrated, in an in vitro perfusion system, that thyrotropin-'Abbreviation used in this paper: TRH, thyrotropinreleasing hormone. The nomenclature proposed by Li (20) Light microscopy revealed that all of the pituitary adenomas were chromophobe. A normal anterior pituitary was obtained from a woman aged 49 yr at the time of hypophysectomy for pallidation of metastatic breast cancer. The method for preparing the dispersed cells employed in this study is a modification of the procedure originally described by Lambert et al. (22) . Pituitary adenoma or normal pituitary tissue was cut into small pieces and incubated with 10 ml of trypsin-collagenase solution with gentle magnetic stirring at 37°C. This solution contained 0.25 g trypsin (Difco Laboratories, Detroit, Mich.), 20 mg collagenase (type IV; Worthington Biochemical Corp., Freehold, N. J.) and 0.05 g glucose in 100 ml of Ca++-free, Mg++-free phosphate buffered saline (pH 7.6). After 10 min of incubation, residual tissues were alowed to settle. The supernatant suspension containing dissociated cells were removed, diluted with cold culture medium, and kept on ice until the final centrifugation. Another 10 ml of trypsin-collagenase solution was added to the remaining tissue fragments and the digestion procedure was repeated two to three times-until cells were completely dispersed. The supernatant fluids were then pooled and centrifuged at 150 g for 10 min. After decantation of the supemate, the cell pellet was washed with culture medium and again centrifuged. Cells were resuspended in an appropriate volume (usually 60 ml) of culture medium by drawing repeatedly through a Pasteur pipette. 2-ml aliquots containing -100,000 cells was planted in each plastic petri dish ( labeled ACTH or incubation medium were placed in each tube and an appropriate amount of 0.1 M phosphate buffer, pH 7.4, including 0.5% human serum albumin, 0.5% 2-mercaptoethanol and 500 U/ml aprotinin was added to yield a volume of 300 ul. To this was then added 100 ,ul of diluted anti-ACTH serum and labeled ACTH (2,500 cpm), and incubation was performed at 4°C for 5d. Antibody-bound and free hormone were separated by use of polyethylene glycol (25) . The lower limit of the sensitivity was 2 pg/tube. The coefficients of variation averaged 7.3% for intra-assay error and 11.4% for interassay error. When plasma samples were assayed, 20-200 pAl of plasma was used with a larger volume of assay buffer to yield the final volume of 1 ml. To validate the ACTH assay with raw plasma, 20, 50, or 200 ,ul of unextracted plasma (five or six samples in each group) with various ACTH concentrations ranging from 51 to 7,400 pg/ml was assayed and the results were compared with the values obtained by radioimmunoassay after adsorption onto glass microbeads by the method of Rees et al. (26) . When the ACTH concentrations in unextracted plasma were plotted on the ordinate and the estimates by the extraction method on the abscissa, a linear regression line with a slope of 0.98 and an intercept of 11 pg (r = 0.999, n = 16) was pbtained, which demonstrates that raw plasma does not interfere significantly in the present ACTH radioimmunoassay.
Statistical analysis. Values in figures and text are given as the mean+SEM, unless otherwise specified. The significance of differences was calculated using Student's t test and analysis of variance.
RESULTS
Plasma ACTH response to TRH, cyproheptadine, and hydrocortisone. Since and 225+25.1 pg/ml (patient 5), respectively. On the basis of this finding, the response was judged to be positive to a given stimulus in the following study when an elevation or a reduction in plasma ACTH concentrations exceeded twice the standard deviation from the mean value, that is, 15.1 (patient 1), 22.5 (patient 2), 15.7 (patient 3), and 22.3% (patient 5) of each control level, respectively. Fig. 1 shows the changes in plasma ACTH concentrations in response to TRH injection in four patients. TRH-induced ACTH release in all of the three subjects with Nelson's syndrome tested (patients 1-3). Plasma ACTH peaked at 15-60 min after the injection and peak values were 319 (patient 1), 226 (patient 2), and 168% (patient 3) oftheir control levels, respectively. The patient with Cushing's disease (patient 5) showed a small gradual rise in plasma ACTH concentrations after TRH administration, but the pattern was different from other patients. Fig. 2 shows the effect of cyproheptadine administration on plasma ACTH concentrations in two patients with Nelson's syndrome (patients 1 and 3). A single dose of cyproheptadine resulted in a slight but a significant decrease in plasma ACTH levels in both patients. The lowest values were obtained at 150 or 180 min after the administration, and corresponded to 73.6 (patient 1) and 67.3% (patient 3) of their control levels, respectively, which were lower than the mean-3 SD of spontaneous fluctuation in each patient. In one patient (No. 1), plasma ACTH levels tended to rise again at 180 min after the administration, whereas the suppressive effect of cyproheptadine was continued during the period of observation in the other (patient 3). (mean+SEM, n = 6).
Effect of cyproheptadine on ACTH secretion from cultured pituitary adenoma cells. The effect ofcyproheptadine on ACTH release by cultured pituitary adenoma cells is illustrated in Fig. 5 . When cyproheptadine was added to the incubation medium, ACTH secretion was significantly suppressed in all of the five experiments using different adenoma tissues. In three adenoma cells (Nos. 1-3) obtained from patients with Nelson's syndrome, cyproheptadine at a concentration of 0.1 ,uM resulted in a significant decrease in ACTH released into the medium by 48.3 (No. 1) (P < 0.01), 27.3 (No. 2) (P < 0.01), and 12.6% (No. 3) (P < 0.05), respectively, compared with each control. Although cyproheptadine at the same concentration was ineffective in lowering ACTH secretion in the remaining two adenoma tissues (Nos. 4 and 5), a significant decrease (P < 0.01) in ACTH release was observed with a higher concentration (1 ,uM Cells were incubated at 37°C in 2 ml of Minimum Essential Medium (Eagle) in Earle's solution containing 0.5% human serum albumin (preincubation). After 1 h, the medium was removed and cells were further incubated with 2 ml of fresh medium for 2 h (experimental incubation (Fig. 1) . Moreover, a dose-response curve was obtained between the concentrations of TRH and ACTH response (Fig. 7) . In the same adenoma cells hydrocortisone (1 uM) caused a significant (P < 0.05) suppression of ACTH release (Fig. 7 ). An inverse dose-response relationship was observed between hydrocortisone and ACTH accumulation in the medium.
To examine the interaction between the stimulatory effect of TRH and the suppressive action exerted by cyproheptadine as well as by hydrocortisone on ACTH release, the following experiments were performed. The cultured cells from patient 2 also responded to 0.1 ,uM TRH by secreting ACTH (P < 0.05) (Fig. 8) .
When cyproheptadine was coincubated with TRH, this stimulatory effect of TRH was overcome. In adenoma cells from patient 3, TRH at a concentration of 0.1 1,M did not show any significant effect, while 0.1 ,M hydrocortisone inhibited ACTH release (P < 0.05) (Fig. 8) . When cells were incubated with TRH and hydrocortisone at an equimolar concentration, the inhibitory effect of hydrocortisone disappeared. Hydrocortisone at a higher concentration (1 ,uM), however, effectively abolished the effect of TRH. TRH had no stimulatory effect on cultured cells from patient 5, which was consistent with the observation that TRH injection failed to elevate plasma ACTH concentrations in this patient (Fig. 1) is depicted in Fig. 9 . The addition of hydrocortisone at a concentration of 0.1 ,uM to the culture resulted in a significant decrease in ACTH release (P < 0.01) by -50%. Conversely, incubation of cells with synthetic lysine vasopressin (0.1 ,uM) stimulated the cultured corticotrophs to secrete ACTH significantly, compared with controls (P < 0.01). In contrast, cells did not show any response to cyproheptadine, dopamine, and TRH at 1 ,uM. DISCUSSION Paradoxical or aberrant ACTH response to TRH has been recently described in patients with Cushing's disease and in those with Nelson's syndrome (29, 30) . The mechanism and the site of action of TRH to induce ACTH release in this pathological condition are unknown. TRH may act on the hypothalamus, as suggested by Krieger et al. (8, 29) ; or alternatively TRH may possess a direct action on pituitary adenoma of these patients to stimulate ACTH secretion. On the basis of our previous findings that anomalous growth hormone responses in acromegalics could be explained by the effect of TRH on pituitary tumors at a cellular level (21, 31) , the latter explanation seemed to us to be more likely. We then examined the effect of TRH on ACTH secretion using cultured pituitary adenoma cells obtained from patients with Cushing's disease and Nelson's syndrome in the present study. In adenoma cells from two subjects whose plasma ACTH levels rose in response to TRH injection before surgery, a significant increase in ACTH secretion in vitro was observed. That this effect of TRH on ACTH release is merely an artifact is unlikely, since a dose-response relationship was observed in one experiment between TRH concentrations and the response ofACTH (Fig. 7) . Moreover, adenoma cells from a patient with Cushing's disease (patient No. 5) who failed to show ACTH response to TRH in vivo, again did not respond to TRH in vitro. The observation that TRH was inactive in triggering ACTH release from normal human corticotrophs (Fig. 9) (33, 34) . Serotoninergic blockade by cyproheptadine, therefore, may inhibit ACTH secretion by hypothalamic inhibition in patients with Cushing's disease and in those with Nelson's syndrome. Altered central nervous system function was postulated in these patients (1, 29, 34) . However, a significant decrease in immunoreactive ACTH released into the medium, compared with control incubation, was observed when cyproheptadine was added to adenoma cells at a concentration of 0.1 or 1 ,uM (Fig. 5) . Furthermore, coincubation of cells with serotonin blocked this inhibitory effect of cyproheptadine, which may indicate that the action of this drug is mediated by its antiserotoninergic property. In contrast, normal human corticotrophs did not show any response to cyproheptadine at 1 ,uM (Fig. 9) . These results suggest that cyproheptadine may exert a direct action on pituitary corticotroph adenoma to inhibit the hormone secretion. Favoring of this view is the clinical observation that cyproheptadine was effective in lowering ACTH levels in a patient with an ectopic ACTHproducing tumor (35) . When TRH was coincubated with cyproheptadine, the stimulatory effect of TRH on ACTH release was overcome. Similarly, hydrocortisone at a higher concentration blocked TRHmediated ACTH secretion (Fig. 8) (27) . Similarly, 5-hydroxytryptophan was also ineffective in this regard (Fig. 5) . The reason why adenoma cells responded to cyproheptadine but not to serotonin remains unknown. In addition to cyproheptadine, the therapeutic action of bromocriptine in Cushing's disease has been evaluated in recent years (9) (10) (11) (12) (13) (14) (15) . A marked diminution of plasma ACTH after a single oral dose of bromocriptine has been observed in some patients with the disease as well as in subjects with Nelson's syndrome (9) (10) (11) (12) 15) , although other workers failed to demonstrate such an effect (13, 14) . In the present study, 0.1 ,uM dopamine inhibited the release of ACTH in all of the five adenoma cells studied. That this was simply caused by nonspecific action of dopamine is unlikely, since coincubation of cells with haloperidol resulted in the reversal of dopamine effect. Moreover, the inhibitory effect of dopamine on ACTH secretion was not observed in normal human corticotrophs in culture (Fig. 9) . Thus, it may be plausible to ascribe the effect of bromocriptine, a specific dopamine receptor agonist with a prolonged action, to a direct inhibition of ACTH release from corticotroph adenoma cells in these patients. Compared with the previous reports on the efficacy of bromocriptine in patients with Cushing's disease (9) (10) (11) (12) (13) (14) (15) , the percentage of responders in the present study ( (1 ,uM) (Fig. 7) . The addition of hydrocortisone at the lower concentration resulted in a modest but a significant decrease in ACTH secretion in the other (No. 3) (Fig. 8) . These results suggest that hydrocortisone inhibits ACTH secretion by acting on adenoma cells of these patients. The site of corticosteroid-feedback control of ACTH in men has not been clarified, but a number of studies hitherto obtained in experimental animals favor the pituitary level (36) (37) (38) (39) . In fact, ACTH secretion from cultured normal human corticotrophs was markedly suppressed by hydrocortisone at the lower concentration (0.1 ,M). The abnormalities of steroid feedback regulation in Cushing's disease and in Nelson's syndrome, therefore, could be largely explained by altered putative steroid receptors on adenoma cells, which may be less sensitive when compared with those of normal corticotrophs.
The present study has provided the evidence for the ability of a direct action of cyproheptadine and dopamine, as well as hormones including TRH and hydrocortisone, on corticotroph adenomas to affect ACTH secretion. The precise mechanism of the action of these substances, however, remains unknown. The fact that some patients respond to these stimuli while others do not is difficult to explain. Further studies may be necessary for the solution of these questions.
